News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Relypsa, Inc. Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia


5/13/2013 10:05:17 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Relypsa, Inc., a clinical-stage biopharmaceutical company, today announced that the company has completed enrollment of its pivotal phase 3 program of patiromer for the treatment of hyperkalemia in patients with chronic kidney disease (CKD). The two part phase 3 clinical trial is being conducted under an agreed upon special protocol assessment (SPA) with the U.S. Food and Drug Administration as follows:

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES